Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells
Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells
复制标题
thiazolidinedione 和 肼苯哒嗪的组合通过 PPARγ 上调表达 MDA-MB-231 细胞抑制增殖并诱导细胞凋亡。
DOI：
10.1016/j.yexmp.2011.09.007
复制
发表时间：
2011-12-01
影响因子：
3.6
通讯作者：
Shen, Aiguo
中科院分区：
文献类型：
--
作者：
Jiang, Ying;Huang, Yeqing;Shen, Aiguo
目前没有经证实的靶向疗法可用于治疗三阴性乳腺癌（TNBC）。过氧化物酶体激活受体（peroxisome-activated receptor，PPARgamma）的配体激活在肿瘤中诱导抗肿瘤作用，但在TNBC中不明显。在TNBC细胞中，噻唑烷二酮和去甲基化药物肼屈嗪联合治疗上调了PPAR γ的蛋白和mRNA水平。此外，两种药物的组合促进TNBC细胞中的抗增殖和凋亡作用，并降低肿瘤异种移植物中的增殖指数。总之，我们的结果表明，包括噻唑烷二酮和肼苯哒嗪组合的多药方案可能在TNBC中提供治疗优势。(C)2011 Elsevier Inc. All rights reserved.
No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Ligand activation of peroxisome-activated receptor (PPAR)gamma induces antitumor effects in cancer but not obviously in TNBC. In TNBC cells, combined treatment with thiazolidinedione and demethylation drugs Hydralazine up-regulated protein and mRNA levels of PPAR gamma. Besides, the combination of two drugs promote antiproliferative and apoptotic effects in TNBC cells and decrease the proliferation index in the tumor xeno-grafts. Taken together, our results suggest that multidrug regimens including a combination of Thiazolidinedione and Hydralazine may provide a therapeutic advantage in TNBC. (C) 2011 Elsevier Inc. All rights reserved.